ACTRN12608000574347已完成1 期
A Phase I study to assess the bioavailability of topically applied Diclofenac in combination with the novel penetration enhancer Tocopheryl Phosphate Mix (TPM), compared with Voltaren Gel in 12 healthy male or female participants.
Phosphagenics Limited0 个研究点目标入组 12 人开始时间: 2008年11月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1. Mare or female, aged between 18 to 55 years, inclusive.
- •2. Healthy, defined as free from clinically significant illness or disease as determined by their medical history, physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory determinations.
- •3. Have Body Mass Index (BMI) 19-30kg/m2 and weight > 50 kg.
- •4. Have adequate venous access on left or right arm to allow collection of a number of samples.
- •5. Are willing to undergo frequent blood sampling.
- •6. Fluent in the English language.
- •7. Able to understand and sign the written Informed Consent Form.
- •8. Willing to follow the protocol requirements and comply with protocol restrictions.
- •9. Individuals free of any dermatological or systemic disorder that will interfere with the results, at the discretion of the Investigator.
排除标准
- •Exclusion Criteria:
- •1. Hypersensitivity to, or persons considered at increase risk of hypersensitivity to diclofenac; other non-steroidal anti-inflammatory drugs (NSAIDS) such as arylalkanoic acids (indomethacin), salicylates (aspirin), profens (ibuprofen), fenamic acids, pyrazolidine derivates (phenazone), ozicams (piroxicam), COX-2 inhibitors (celecoxib), sulphonanilides (nimesulid); propylene glycol, isopropyl alcohol or other ingredients of the gel; or any other medications.
- •2. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs or any other medications.
- •3. Treatment with any medication that may mask or interfere with the results, including: another non-steroidal anti-inflammatory drug (NSAIDS), aspirin, corticosteroids, cyclosporine, methotrexate, digoxin, lithium, warfarin or any other anticoagulants or blood thinning medications.
- •4. Participation in any clinical trial during the 30 days preceding the screening period for this trial.
- •5. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in section 9.4.6 from at least 14 days prior to the first dose of trial medication until completion of follow-up procedures.
- •6. Blood donation within 28 days prior to screeing.
- •7. is planning to have surgery, including dental surgery at any point during the trial.
- •8. Individuals diagnosed with chronic, contagious viral infections such as Human Immunodeficiency Virus (HIV), hepatitis or herpes.
- •9. Participants diagnosed with diabetes mellitus, stomach and/or duodennal ulceration or gastrointestinal bleeding, hemorrhoids, inflammative intestinal disorders such Crohn's disease or ulcerative colitis, kidney stones, renal insufficiency, cardiovascular failure, fluid retention (swelling of feet or edema), anemia, hepatic porphyria, asthma, epilepsy, Parkinson's disease or any disease that would increase the risk associated with study participation.
- •10. Participants with a history of any form of skin cancer, melanoma, lupus, psoriasis, connective tissue disease, diabetes or any disease that would increase the risk associated with study participation.
- •11. Individuals diagnosed with chronic skin allergies.
- •12. Individuals with blemishes, nevi, sunburn, suntan, scars, moles, active dermal lesions, uneven pigmentation in the test sites.
- •13. Individuals with known hypersensitivity to cosmetic products in general and moisturizers in particular.
研究者
相似试验
进行中（未招募）
不适用
A study to compare a pediatric tablet or suspension of elvitegravir verses the adult 150 mg tablet in healthy adult volunteersHuman Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2015-000725-37-Outside-EU/EEAGilead Sciences, Inc.78
尚未招募
1 期
TASK 011-RPT-Crush:Relative bioavailability of three generic rifapentine and isoniazid compounds when manipulated in adults with latent tuberculosis: a bridge to paediatric dosing needs (RPT CRUSH”)TuberculosisPACTR202306775627089Stellenbosch University24
已完成
1 期
A phase I study to compare the bioavailability and pharmacokinetics of fentanyl after administration of a single dose of a Fentanyl MDTS and a Durogesic 25 patch in paiPainOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12605000526673Acrux DDS Pty Ltd6
进行中（未招募）
1 期
Evaluation of efficacy and bioavailability of ibuprofen lysinatePain on an inflammatory basis (otitis and otomastoiditis, adenite, cellulite, arthritis) and post-operative painMedDRA version: 21.0Level: PTClassification code 10050533Term: Pain assessmentSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: LLTClassification code 10063374Term: Pain scaleSystem Organ Class: 10022891 - InvestigationsEUCTR2019-000647-27-ITDicofarm S.p.A.84
已完成
1 期
A Phase 1 Study of Two PRN1008 Tablet Formulations and the impact of Midazolam and Famotidine on PRN1008 in Healthy SubjectsACTRN12618000249257Principia Biopharma Inc14